Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.23 USD | +1.68% | -11.75% | +55.02% |
05-15 | Spyre Therapeutics, Inc. Announces Board Changes | CI |
05-13 | Wells Fargo Adjusts Price Target on Spyre Therapeutics to $40 From $35, Maintains Overweight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.02% | 1.32B | |
+12.13% | 116B | |
+12.71% | 106B | |
-9.82% | 23.89B | |
-1.69% | 21.58B | |
-10.60% | 18.96B | |
-41.25% | 16.96B | |
-14.92% | 16.33B | |
+6.16% | 14.14B | |
+29.40% | 12.02B |
- Stock Market
- Equities
- SYRE Stock
- News Spyre Therapeutics, Inc.
- Transcript : Aeglea BioTherapeutics, Inc. - Shareholder/Analyst Call